Facebook
Twitter
LinkedIn

Media Center

FAST, Fellows & CARB-X Update | January 2021
Facebook
Twitter
LinkedIn

FAST & Fellows

BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) and Eidos Therapeutics, Inc. (“Eidos”) (FAST Spring 2016) (Nasdaq: EIDX) have announced that the stockholders of each of BridgeBio and Eidos voted to approve all proposals related to BridgeBio’s acquisition of all of the outstanding shares of Eidos common stock that BridgeBio does not already own. The merger closed on January 26, 2021, when at a special meeting of Eidos stockholders, Eidos stockholders approved the adoption of the previously disclosed merger agreement with BridgeBio and each of the other proposals related to BridgeBio’s proposed acquisition of Eidos. Read more.

CARB-X

CARB-X is funding a team of top German researchers to develop a drug to treat Staphylococcus aureus infections and prevent exacerbation of life-threatening pneumonia. CARB-X is awarding researchers from the Helmholtz Centre for Infection Research (HZI) and the Lead Discovery Center GmbH (LDC) up to US$8.77 million to develop a new drug to disable S. aureus pathogens thereby preventing lung infections. Read More.

CARB-X is funding a German team of scientists to develop a new treatment for difficult-to-treat Pseudomonas aeruginosa infections in cystic fibrosis patients. CARB-X is awarding up to US$1.75 million to the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) in Saarbrücken, Germany, to develop an innovative treatment for Pseudomonas aeruginosa infections in cystic fibrosis patients. Read More.

CARB-X honored with award from the Global Health Technologies Coalition for progress made in accelerating R&D to combat drug-resistant bacteria. CARB-X has been awarded the 2020 Partnership Award by the Global Health Technologies Coalition (GHTC) for its work in accelerating R&D. The award recognizes CARB-X’s progress in expanding the pipeline of innovation that address one of the world’s most pressing public health crises, antibiotic-resistant bacteria. Read More.

2020 a year of remarkable progress in supporting the development of new antibiotics, vaccines, diagnostics and other products targeting antibiotic-resistant bacteria. CARB-X has made solid progress in 2020, providing funding and support for innovative products in the race against antibiotic-resistant bacteria, and significantly building the size and scientific diversity of its global portfolio of antibiotics, vaccines, diagnostics and other life-saving products targeting drug-resistant bacteria. Read More.